Stephen W. Fesik

44.4k total citations · 14 hit papers
267 papers, 31.1k citations indexed

About

Stephen W. Fesik is a scholar working on Molecular Biology, Oncology and Spectroscopy. According to data from OpenAlex, Stephen W. Fesik has authored 267 papers receiving a total of 31.1k indexed citations (citations by other indexed papers that have themselves been cited), including 219 papers in Molecular Biology, 42 papers in Oncology and 40 papers in Spectroscopy. Recurrent topics in Stephen W. Fesik's work include Cell death mechanisms and regulation (38 papers), Signaling Pathways in Disease (36 papers) and Protein Kinase Regulation and GTPase Signaling (26 papers). Stephen W. Fesik is often cited by papers focused on Cell death mechanisms and regulation (38 papers), Signaling Pathways in Disease (36 papers) and Protein Kinase Regulation and GTPase Signaling (26 papers). Stephen W. Fesik collaborates with scholars based in United States, United Kingdom and Germany. Stephen W. Fesik's co-authors include Edward T. Olejniczak, Philip J. Hajduk, Robert Meadows, Andrew M. Petros, John E. Harlan, Suzanne B. Shuker, Ho Sup Yoon, Erik R. P. Zuiderweg, David G. Nettesheim and Heng Liang and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Stephen W. Fesik

264 papers receiving 30.3k citations

Hit Papers

Discovering High-Affinity Ligands for Proteins: SAR by NMR 1994 2026 2004 2015 1996 2008 2014 1997 1996 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Discovering High-Affinity Ligands for Proteins: SAR by NMR
    1996 1.6k citations Philip J. Hajduk, Stephen W. Fesik et al. profile →
  2. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
    2008 1.5k citations Christin Tse, Alexander R. Shoemaker et al. Cancer Research profile →
  3. Drugging the undruggable RAS: Mission Possible?
    2014 1.4k citations Stephen W. Fesik et al. profile →
  4. Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
    1997 1.2k citations David G. Nettesheim, Stephen W. Fesik et al. profile →
  5. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
    1996 1.2k citations David G. Nettesheim, Shi‐Chung Ng et al. profile →
  6. Promoting apoptosis as a strategy for cancer drug discovery
    2005 929 citations Stephen W. Fesik profile →
  7. Twenty years on: the impact of fragments on drug discovery
    2016 684 citations Daniel A. Erlanson, Stephen W. Fesik et al. profile →
  8. Bcl-xL forms an ion channel in synthetic lipid membranes
    1997 682 citations Stephen W. Fesik et al. profile →
  9. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate
    1994 656 citations Philip J. Hajduk, Stephen W. Fesik et al. profile →
  10. Structural Basis for the Inhibition of Caspase-3 by XIAP
    2001 592 citations Stephen W. Fesik et al. profile →
  11. Structural biology of the Bcl-2 family of proteins
    2003 582 citations Andrew M. Petros, Edward T. Olejniczak et al. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research profile →
  12. 14-3-3 Proteins and Survival Kinases Cooperate to Inactivate BAD by BH3 Domain Phosphorylation
    2000 532 citations Andrew M. Petros, Stephen W. Fesik et al. profile →
  13. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain
    2000 511 citations Edward T. Olejniczak, Thorsten Oost et al. profile →
  14. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
    2017 479 citations Taekyu Lee, Stephen W. Fesik et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen W. Fesik United States 86 24.8k 5.3k 3.4k 3.1k 2.7k 267 31.1k
Paul Workman United Kingdom 85 18.6k 0.8× 5.8k 1.1× 2.3k 0.7× 2.7k 0.9× 2.6k 1.0× 535 27.7k
John Kuriyan United States 99 28.8k 1.2× 7.0k 1.3× 3.6k 1.0× 2.0k 0.7× 1.4k 0.5× 235 38.8k
Tom L. Blundell United Kingdom 94 34.2k 1.4× 3.5k 0.7× 2.5k 0.7× 3.3k 1.1× 5.3k 2.0× 505 45.7k
Stefan Knapp Germany 91 21.6k 0.9× 5.6k 1.0× 1.8k 0.5× 3.7k 1.2× 2.1k 0.8× 516 29.0k
Shaomeng Wang United States 91 20.8k 0.8× 7.0k 1.3× 1.7k 0.5× 5.4k 1.7× 4.6k 1.7× 459 29.3k
Warren L. DeLano United States 15 24.4k 1.0× 2.7k 0.5× 2.5k 0.7× 2.2k 0.7× 1.5k 0.6× 17 33.1k
Susan S. Taylor United States 98 29.1k 1.2× 3.5k 0.7× 1.5k 0.4× 1.4k 0.4× 2.7k 1.0× 462 35.7k
Gerhard Wagner United States 106 29.7k 1.2× 3.0k 0.6× 4.3k 1.3× 2.5k 0.8× 830 0.3× 535 41.9k
S.K. Burley United States 86 23.1k 0.9× 2.0k 0.4× 1.4k 0.4× 1.9k 0.6× 1.7k 0.6× 333 33.0k
Nathanael S. Gray United States 104 30.5k 1.2× 10.9k 2.1× 3.2k 0.9× 5.0k 1.6× 2.3k 0.9× 476 42.2k

Countries citing papers authored by Stephen W. Fesik

Since Specialization
Citations

This map shows the geographic impact of Stephen W. Fesik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen W. Fesik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen W. Fesik more than expected).

Fields of papers citing papers by Stephen W. Fesik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen W. Fesik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen W. Fesik. The network helps show where Stephen W. Fesik may publish in the future.

Co-authorship network of co-authors of Stephen W. Fesik

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen W. Fesik. A scholar is included among the top collaborators of Stephen W. Fesik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen W. Fesik. Stephen W. Fesik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fesik, Stephen W.. (2025). Drugging Challenging Cancer Targets Using Fragment-Based Methods. Chemical Reviews. 125(6). 3586–3594. 1 indexed citations
2.
Arai, Kenta, Michelle R. Arkin, Daniel A. Erlanson, et al.. (2025). Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective. Journal of Medicinal Chemistry. 68(23). 24830–24847.
3.
Meyer, Christian T., Jing Wang, Brian C. Grieb, et al.. (2024). Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies. Proceedings of the National Academy of Sciences. 121(35). e2408889121–e2408889121. 4 indexed citations
4.
Tian, Jianhua, Changho Han, Kenneth M. Meyers, et al.. (2023). Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors. Journal of Medicinal Chemistry. 66(24). 16783–16806. 7 indexed citations
5.
Howard, Gregory C., Jing Wang, Kristie L. Rose, et al.. (2023). Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. eLife. 12. 9 indexed citations
6.
Guarnaccia, Alissa D., Kristie L. Rose, Jing Wang, et al.. (2021). Impact of WIN site inhibitor on the WDR5 interactome. Cell Reports. 34(3). 108636–108636. 36 indexed citations
7.
Howes, Jennifer E., et al.. (2018). Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1. Molecular Cancer Therapeutics. 17(5). 1051–1060. 31 indexed citations
8.
Ramsey, Haley E., Melissa A. Fischer, Taekyu Lee, et al.. (2018). A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discovery. 8(12). 1566–1581. 254 indexed citations
9.
Li, Xia, Navdeep S. Chandel, Xiaoli Huang, et al.. (2008). A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proceedings of the National Academy of Sciences. 105(1). 174–179. 85 indexed citations
10.
Tse, Christin, Alexander R. Shoemaker, Jessica Adickes, et al.. (2008). ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Research. 68(9). 3421–3428. 1513 indexed citations breakdown →
11.
Ackler, Scott, Xiao Yu, Michael J. Mitten, et al.. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 7(10). 3265–3274. 64 indexed citations
12.
Tahir, Stephen K., Xiufen Yang, Mark G. Anderson, et al.. (2007). Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737. Cancer Research. 67(3). 1176–1183. 250 indexed citations
13.
Petros, Andrew M., Jürgen Dinges, David J. Augeri, et al.. (2005). Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis. Journal of Medicinal Chemistry. 49(2). 656–663. 229 indexed citations
14.
Hajduk, Philip J., Jeffrey R. Huth, & Stephen W. Fesik. (2005). Druggability Indices for Protein Targets Derived from NMR-Based Screening Data. Journal of Medicinal Chemistry. 48(7). 2518–2525. 387 indexed citations
15.
Petros, Andrew M., Angelo Gunasekera, Nan Xu, Edward T. Olejniczak, & Stephen W. Fesik. (2004). Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR. FEBS Letters. 559(1-3). 171–174. 83 indexed citations
16.
Yu, Liping, et al.. (2003). Discovery of Aminoglycoside Mimetics by NMR-Based Screening of Escherichia c oli A-site RNA. Journal of the American Chemical Society. 125(15). 4444–4450. 70 indexed citations
17.
Petros, Andrew M., Edward T. Olejniczak, & Stephen W. Fesik. (2003). Structural biology of the Bcl-2 family of proteins. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1644(2-3). 83–94. 582 indexed citations breakdown →
18.
Huang, Qiulong, Andrew M. Petros, Herbert W. Virgin, Stephen W. Fesik, & Edward T. Olejniczak. (2002). Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proceedings of the National Academy of Sciences. 99(6). 3428–3433. 103 indexed citations
19.
Makriyannis, Alexandros, et al.. (1991). Anesthetic steroid mobility in model membrane preparations examined by high-resolution proton and deuterium NMR spectroscopy. Journal of Medicinal Chemistry. 34(5). 1700–1703. 20 indexed citations
20.
Fesik, Stephen W., Ian M. Armitage, George A. Ellestad, & William J. McGahren. (1984). Nuclear magnetic resonance studies on the interaction of avoparcin with model receptors of bacterial cell walls.. Molecular Pharmacology. 25(2). 281–286. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Workman Breakdown of academic impact, for papers by John Kuriyan Breakdown of academic impact, for papers by Tom L. Blundell Breakdown of academic impact, for papers by Stefan Knapp Breakdown of academic impact, for papers by Shaomeng Wang Breakdown of academic impact, for papers by Warren L. DeLano Breakdown of academic impact, for papers by Susan S. Taylor Breakdown of academic impact, for papers by Gerhard Wagner Breakdown of academic impact, for papers by S.K. Burley Breakdown of academic impact, for papers by Nathanael S. Gray
Rankless by CCL
2026